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challenges for diabetes care in Italy
Federico Grimaccia1,2* and Panos Kanavos1Abstract
Background: In Italy both incidence and prevalence of diabetes are increasing and age at diagnosis is decreasing
in type 2 diabetes. Diabetes is one of the major causes of morbidity in Italy, causing several disabilities and affecting
the economically active population. The objective of this paper is to identify and discuss costs, outcomes and some
of the challenges of diabetes care in Italy in the context of recent policy changes.
Methods: The study collected data and evidence from both primary and secondary sources. A total of 10 experts,
including clinicians (diabetologists/endocrinologists) and decision makers, both at national and regional levels, were
interviewed through face-to-face semi-structured interviews. The secondary sources include peer review literature
from Medline, grey literature, reports from national and international sources, including professional bodies and
organizations.
Results: The total direct cost of diabetes for the Italian NHS in 2012 is estimated to be above €9 billion, of which
more than half for hospital admissions (57%), and the remaining half for drugs (30%) and outpatient care (13%).
However, there is scant evidence on indirect and intangible costs of diabetes in Italy. The quality of care addressed
via the AMD Annals found overall good performance with both process and intermediate outcome indicators
showing positive and improving results from 2004 to 2011, except for few parameters, including renal function and
foot monitoring, which are still inadequate. Major challenges are the rising diabetes prevalence, the difficulty in
meeting the rising demand for care and the scant development of multidisciplinary delivery of care, especially in
the predominantly ambulatory setting of the Southern diabetes centres.
Conclusions: Prevention of diabetes, especially adopting a multi-sectorial approach, should be further empowered
by policy makers through promoting healthy lifestyles and specifically targeting child obesity. Other key strategies
include more information and education, better diabetes management through the adoption of a chronic model of
care, more focus on appropriateness and efficiency of care and better communication between diabetes centres
within every Region.
Keywords: Diabetes, Italy, Complications, Costs, OutcomesBackground
In Italy both incidence and prevalence of diabetes are
increasing and age at diagnosis is decreasing in type 2
diabetes. According to the national statistical source,
diabetes prevalence has increased from 3.9% in 2001 to
5.4% in 2013, representing currently more than 3 million
Italians with diabetes [1]. Diabetes prevalence is higher in
men (5.6%) than women (5.3%) and increases with age* Correspondence: f.grimaccia@lse.ac.uk
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Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumreaching a prevalence of 20.4% in people older than 75.
In general, prevalence is higher in the South of Italy and
the Islands (6.6%) than in the Centre and North of Italy
(respectively 5.3% and 4.6%). Furthermore, prevalence
seems to be also related to education and social class,
with higher rates in people with no or little education
and low income [2]. Italy offers a well developed system
in Europe with regard to diabetes care, being the first
European Country to issue a specific law on diabetes,
the Law 115 of 1987 [3]. One of the main contributions
of this law is the institutionalization of diabetes centres
which have since developed to form a wide networked Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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680 diabetes centres evenly distributed throughout the
20 Italian Regions, roughly one centre every 100.000
inhabitants [4]. This high distribution of diabetes centres
enables decentralized care, with most diabetic patients
referred to their local diabetes centre. The organization
of diabetes care is ensured by dedicated diabetes Com-
missions, both at national and regional level. The
National Diabetes Commission was created by the
Ministry of Health in 2003 to coordinate all stake-
holders involved in diabetes care as well as monitor the
implementation of the guidelines set by Law 115. The
Commission includes representatives from all the main
stakeholder groups dealing with diabetes: the Ministry
of Health (General Direction of Planning and General
Direction of Prevention), regional delegates, scientific
societies, voluntary associations and patient associa-
tions [5]. Similarly, Regional Diabetes Commissions,
represented by all local diabetes stakeholders, aim to
coordinate activities and initiatives at regional level.
Italy has just recently issued the first National Diabetes
Plan in response to the European Parliament reso-
lution of 12 March 2012 [6]. The objective of the
National Plan is to provide guidelines to improve the
quality of diabetes care and consistency among pro-
grammes and initiatives implemented at regional level.
In Italy all diabetes care expenses are fully covered by
the National Health Service (NHS), with no out-of-
pocket payments. In fact, diabetes care includes the
supply of all drugs and devices according to the Livelli
Essenziali di Assistenza (LEA) (literally “minimum levels
of care”) which represent the minimum services which
must be guaranteed by all Italian Regional Health Systems
[7]. This paper aims at identifying the direct costs of
diabetes, presenting diabetes outcomes and quality of
care and finally discussing the challenges which diabetes
brings for the foreseeable future in Italy.
Methods
The study collected data and evidence from both pri-
mary and secondary sources. A total of 10 experts,
including clinicians (diabetologists/endocrinologists) and
decision makers, both at national and regional levels,
were interviewed face-to-face using a semi-structured
questionnaire between December 2011 and October
2012. Clinicians were interviewed to address the clinical
aspects of diabetes such as diagnosis and treatment.
Moreover, two of them were specifically selected to give
different points of view. In particular, one is a renowned
diabetologist who undertakes research on direct costs of
diabetes using the largest database of diabetic patients
in Italy. The other clinician is the coordinator of the
Annals of the Associazione Medici Diabetologi (AMD)
which represents the main initiative at national level tomonitor diabetes care quality in Italy. Two national deci-
sion makers from the Ministry of Health were interviewed
to investigate their perspectives on the challenges posed
by diabetes at national level. In addition, three regional
diabetes decision makers from Lombardia, Marche and
Puglia were identified to represent regional variations in
organization of diabetes care between North, Centre and
South. The experts were asked about the various elements
and pathways of diabetes care (including prevention, diag-
nosis, treatment, managing of complications, follow-up
and management).
Secondary data sources include peer review literature
from Medline, grey literature, reports from national and
international sources, including professional organizations.
The following key words were used, both in English and
Italian: “Italy + diabetes”; “Italy + diabetes + prevalence”;
“Italy + diabetes + costs”; “Italy + diabetes + costs + compli-
cations”; “Italy + diabetes + outcomes”; “Italy + diabetes +
guidelines”. Studies were selected on the basis of their
abstracts or executive summaries. Articles and reports
were included based on their relevance with any of the
following variables: costs, treatment and quality of dia-
betes care. The selected articles were then read in full to
extract data of interest.
Result and discussion
Cost of diabetes in Italy
All recent studies on cost of diabetes in Italy have been
undertaken at a local level. Only one study has been
conducted at national level in Italy to date. This was
undertaken in 1998 as part of the wider CODE 2 (Cost
of Diabetes in Europe-Type 2) study which involved 8
European Countries [8]. This study was an observational
bottom-up study of 1,263 patients selected from diabetes
centres (mainly located in public hospitals) and general
practitioners (GPs) via questionnaires. According to the
results of the study the cost per diabetic patient in Italy
was circa 6 million lire (€2,991) [8], more than double
(221%) the average health care expenditure per person.
The total Italian NHS diabetes expenditure was appro-
ximately 10,500 billion Italian lire (≈ €5.1 billion) [8],
representing 6.65% of the total health expenditure (both
public and private). Overall, the direct costs accounted
for 95.5% with the remainder 4.5% represented by indir-
ect costs. The CODE 2 study also took into account the
intangible costs of type 2 diabetics, showing that the
quality of life was 10% lower than the general popula-
tion. Although the CODE 2 data is more than a decade
old, it is the only study to date looking at direct, indirect
and intangible costs of diabetes in Italy. More recent
analyses of direct costs of diabetes (both type 1 and 2)
have been undertaken at local level using administrative
data (hospital discharge files, pharmaceutical prescrip-
tion and outpatient data) with a top-down approach.
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of administrative data covering a population of appro-
ximately 10 million people living in 32 Health Local
Authorities (ASL) from 8 out of the 20 Italian Regions
and including almost 550,000 diabetic patients. To
date, the ARNO-CINECA Observatory released two
reports, the first in 2007 [9] and the second in 2011
[10] with data referring to 2006 and 2010 respectively.
The ARNO-CINECA analyses compare the diabetic
patients with pharmacologically treated subjects with-
out diabetes, pair-matched for age and gender. According
to the results, the average pro capita cost of a treated
diabetic patient totaled €2,756 in 2010 compared to the
matched non-diabetic control group of €1,545, with the
extra cost being largely related to complications, pri-
marily cardiovascular disease [10]. This represents an
increase in comparison with 2006 when the same costs
were respectively €2,589 and €1,682 [9]. More than half
(57%) of the total diabetes costs in 2010 were for
hospital admissions, while the remaining part was spent
on drugs (30%, of which only 21% was for glucose-
lowering drugs) and on outpatient care (13%). Based on
these data, the total direct cost of diabetes for the Italian
NHS in 2012 has been estimated to be above €9 billion,
corresponding to almost 10% of the total NHS expend-
iture (unpublished observations during interview with
key expert). This represents a substantial increment in
comparison to the €6,64 billion estimated for 2006. A
number of other smaller local studies, which also used
administrative data in a top-down fashion, confirmed
the high impact of complications in driving the cost of
diabetes. The Emilia Romagna Region found that 18% of
the total health expenditure in 2007 was due to type 2
diabetes. Resources absorbed by diabetic patients were
almost threefold compared to patients without diabetes
(€3,124 vs. €1,124/patient annually), mostly due to the
complications such as infarction and kidney disease
[11]. In 2003 the Azienda Sanitaria Locale (ASL) of
Brescia undertook a similar costing analysis finding that
type 1 and 2 diabetes accounted for 12% of total ASL
healthcare expenditure, including hospitalization and
drugs which consumed 56.8% and 27.1% respectively
[12]. Costs in 2003 varied from €892 for diabetes alone
to €5,330 for diabetes plus one or more co-morbidities.
The number of co-morbidities increased treatment costs
almost exponentially, with cardiovascular co-morbidities
representing 20% of the total diabetes expenditure.
Another regional study undertaken in Turin examining
drug costs of type 1 and 2 diabetic and non-diabetic
individuals found that annual drug costs were €830.90
per diabetic patient versus €182.80 per non-diabetic,
with diabetes treatments accounting for 18.5% of total
costs [13]. Overall, despite sufficient availability of cost
data at local level, no study since the CODE 2 study of1998 has been undertaken to assess national total dia-
betes costs. Moreover, apart from the CODE 2, no
study has examined indirect diabetes costs.
Outcomes and quality of care
Since 2006, the quality of care delivered by the Italian
diabetes centres has been monitored by the AMD
Association (Italian Association of Diabetologists).
The AMD publishes on a regular basis their AMD
Annals reporting a performance assessment of diabetes
centres who participate voluntarily in the monitoring ini-
tiative. The number of participating diabetes centres
has been steadily increasing from 180 in 2004 to the
currently 320 which cover a population of almost
550,000 diabetic patients (including both patients with
type 1 and type 2 diabetes) from all the 20 Italian Regions
[4]. The AMD Annals include both process and inter-
mediate outcome indicators along with few additional
indicators which measure the intensity/appropriateness
of treatment. Process indicators include a minimum
annual monitoring of HbA1C levels, lipid profile, blood
pressure, renal function, eye and foot conditions. Inter-
mediate outcome indicators include the percentage of
patients meeting certain parameter levels (HbA1C ≤7%
and >8%, C-LDL <100 mg/dl and ≥130 mg/dl, blood
pressure <130/80 mmHg and ≥140/90 mmHg, BMI
<27 kg/m2 and ≥30 kg/m2, presence of microalbumi-
nuria, GFR <60 ml/min) plus some other intermediate
outcome indicators, such as the percentage of smokers
and body weight. Intensity and appropriateness of treat-
ment indicators measure the percentage of patients who
do not reach the target levels despite the appropriate
treatment as well as patients who fail to be treated
despite inadequate levels of certain parameters. Final
outcome indicators of diabetes-related complications
currently remain outside the scope of the AMD Annals.
The latest edition of the AMD Annals (2012) is a longi-
tudinal analysis of 8 years between 2004 and 2011 [12].
The report shows an overall improvement in quality of
care delivered by the participating diabetes centres
both for type 1 and type 2 diabetes. Both process and
intermediate outcome indicators have improved for
metabolic, blood pressure and lipid profile control
from 2004 to 2011 (Figure 1). The proportion of dia-
betic patients who had their HbA1C, blood pressure
and lipid levels monitored increased with a subsequent
raise of patients within the target levels. However, only
half of the diabetic population achieved blood pressure
target levels despite antihypertensive treatment, show-
ing wide room for improvement. In addition, monitor-
ing of renal function, eyes and foot care results still
inadequate, with only a modest improvement between
2004 and 2011. Results for the intermediate outcomes
pertaining to smoking and diet habits show a deterioration
Figure 1 Quality of diabetes care in the Italian diabetes centres between 2004 and 2011. Notes: all quality indicators reported as rates (%).
In blue colour: process indicators; in red colour: intermediate outcomes indicators; in green colour: intensity/appropriateness of treatment indicators.
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patients slightly increasing in the span of 8 years.
Challenges
Diabetes presents several challenges for both the NHS
and the Italian society. The rising prevalence of dia-
betes represents the biggest challenge, posing a real
threat in health and economic terms to the Italian
health system in the future. Prevalence has been stead-
ily increasing over the last decade, and it is projected
to further increase. It has been pointed out that if
prevalence continues to increase at this pace, the
future impact both on society and economy will be no
longer sustainable [14]. Major factors underpinning
rising prevalence are the ageing population and the ris-
ing obesity. Clearly, the ageing population is difficult
to control. Obesity has increased in the last years, as
also shown in the AMD Annals, mostly due to the
unhealthy life styles including poor diet and scarce
physical activity. Obesity is so strongly related to
diabetes that the two conditions together have been
described as “diabesity” [14]. As a result of increasing
diabetes prevalence, meeting the demand for diabetes
care represents a difficult challenge, with diabetes
centres struggling to provide care to a growing number
of diabetic patients. Although diabetes centres are
evenly distributed geographically, in highly populated
Regions such as Lombardia, there is a disproportion
between the low number of diabetes centres and the
high number of diabetic patients. This inability to meetthe demand is also evident in the rural areas, especially
in the South, where the poor coordination between the
professionals involved in the process of care aggravates
the problem. In these areas diabetes centres have
become the main reference point of care for both
uncomplicated and complicated patients, instead of
referring the uncomplicated patients to general practi-
tioners (GPs) and the complicated patients to diabetes
centres (unpublished observations during interview
with key expert). Although prevention represents the
most powerful instrument to arrest the increasing
prevalence, this is scarcely appealing to politicians
since the outcomes of preventive interventions take
years before can be measured. Thus, from the politi-
cians’ point of view, prevention measures are perceived
as less effective than other more immediate health
interventions. As a consequence, in Italy prevention is
not the main focus in diabetes policy, and conse-
quently healthcare expenditure is still more oriented
towards care rather than prevention (unpublished
observations during interview with key expert). An
additional challenge is reflected in the organization
and delivery of care between the North-Centre and the
South. The Northern and Central diabetes centres
are usually integrated within a hospital, providing a multi-
disciplinary team including diabetologists, nurses, nu-
tritionists and other health professionals. Moreover,
the healthcare specialists treating diabetes complications
(ophthalmologist, nephrologists, vascular surgeons, etc.)
provide substantial and continuous support to the diabetes
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centres’ staff, they are able to provide assistance since they
work within the same facility. In contrast, the southern
diabetes centres are often integrated within group
practices (called “poliambulatori”) where the multi-
disciplinary team is often missing leading to an often
poor management of diabetes. In these settings, diabe-
tologists generally work as independent consultants
treating patients on their own without consulting with
a multidisciplinary group. In addition, they undertake
mainly prescribing activities (unpublished observations
during interview with key expert). Another issue affect-
ing the delivery of care is the poor compliance to dia-
betes treatment. This affects particularly those patients
who find it difficult to follow complex treatments which
require self-monitoring and self-drug administration. This
problem is more relevant where a multi-disciplinary
model of care is less developed, such as in the southern
regions (unpublished observations during interview
with key expert). Finally, although diabetes complica-
tions have been in the policy agenda of past National
Prevention Plans, the current rates in Italy are still too
high. Complications still represent the primary prob-
lem of diabetes, both in health and economic terms.
From an economic perspective, complications account for
up to half of all diabetes expenditure whereas uncom-
plicated diabetic patients represent a minority of NHS
expenditure, as insulin and oral anti-diabetic drugs are
not expensive (unpublished observations during inter-
view with key expert). Further, also the indirect costs,
mostly related to complications, account for a substan-
tial part of the economic burden of diabetes affecting
the care system, families, and the productive capabil-
ities of diabetic patients themselves.
Policy options
Prevention, especially through promoting healthy life-
styles, must be enforced in the policy agenda, both at
national and regional levels. Primary diabetes prevention
is effective in decreasing type 2 diabetes incidence and
represents the key tool in arresting the raise of diabetes
prevalence. In addition, prevention of complications is
extremely important to decrease the impact of disability
on individuals and to reduce the high costs associated
with complications. Although enforcing preventive inter-
ventions will raise short term costs, it will help contain
long term costs by reducing diabetes prevalence and
the rate of complications. Specifically addressing obes-
ity is a useful strategy, since obesity represents the
main trigger factor for diabetes. In particular, child-
hood obesity should be addressed implementing nutri-
tion courses and promoting sports and physical
activity in all schools. The project “Guadagnare Salute”
funded by the Ministry of Health in 2007, joining thelarger “Gaining Health” project of the World Health
Organization (WHO), appears to head in this direction
[15]. This project promotes and coordinates a series of
prevention activities across Italy addressing the four
main obesity risk factors of poor diet, physical inac-
tivity, smoking and excessive alcohol consumption.
Effective prevention interventions should address also
areas outside the health system which in turn impact
on health. A multi-sectorial approach is more likely to
be effective in achieving the desired results. For ex-
ample, the cooperation of the education system will be
key in preventing childhood obesity or an adequate city
planning, such as supplying adequate pedestrian areas,
will be crucial to boost physical activity. In this regard,
Italy seems to have started employing multi-sectorial
co-operation. Currently there are a number of agree-
ments between the Ministry of Health and stake-
holders outside the health sector (i.e. schools, gyms,
transport, agriculture, etc.) which guarantee a common
strategy towards diabetes prevention (unpublished ob-
servations during interview with key expert). In order
to empower prevention, diabetes information and edu-
cation are fundamental. All citizens, not only diabetic
patients, must be correctly informed through aware-
ness campaigns about the risks posed by diabetes in-
cluding complications and the benefits of healthy
lifestyles. In addition, diabetic patients should receive
specific education on diabetes, supporting healthy life-
styles as well as treatment regimens and self-management
(unpublished observations during interview with key
expert). Along with prevention, another key aspect in
the fight against diabetes is the adoption of a “chronic
model of care” including multi-disciplinary care. Effi-
cient cooperation between all professionals involved in
diabetes care is a valuable resource to streamline care.
All professionals should have their specific role so that
their synergic and integrated actions can deliver the
most efficient patient outcomes. Integration between
GPs and diabetologists will optimize the care pathways
to patients benefit. Uncomplicated patients who do not
require insulin should be treated by GPs, while com-
plicated patients who require insulin and have poor
glycaemic control together with patients with a new
diagnosis of diabetes should be treated by diabetolog-
ists in diabetes centres. In addition, in case of emer-
gence of diabetes complications, diabetolgists should
refer the patients to the appropriate specialist (unpub-
lished observations during interview with key expert).
In this regard, in 2006, the National Centre for the
Prevention and Control of diseases (CCM, Centro
Nazionale per la Prevenzione ed il Controllo delle
Malattie) together with the National Health Institute
(ISS, Istituto Superiore di Sanità) launched the IGEA
(Integrazione, Gestione e Assistenza per la malattia
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on patient centered care disease management, and co-
ordinates a wide range of regional activities and pro-
jects. Although some areas in Italy have already started
to implement this chronic model of care, in other
areas, especially in the South, this integrate approach
is still largely absent. Together with a better diabetes
management, appropriateness of care is another useful
medium to optimize delivery of care and minimize
financial resources. Recently, the Ministry of Health
has been particularly concerned about appropriateness
of care, commissioning a dedicated group to write
guidelines on appropriateness of care, both for diabetes
and obesity (unpublished observations during inter-
view with key expert). Since the cost of diabetes and
related complications are extremely high, appropriate-
ness together with efficiency represent useful strategies
to avoid the waste of unnecessary resources. Finally,
improved communication and co-operation between
diabetes centres is also important to optimize care
delivery. Currently, Marche Region is the only region
with a developed information network where all dia-
betes centres share the same clinical record within a
unique centralized system. This enables all diabetolog-
ists to collect data and enable smooth communication
between centres. Other Regions have started to follow
this example, but none yet as developed as the Marche
Region. Such a unique intraregional network should be
empowered in all regions in order to facilitate monitor-
ing of quality in relation to the resources employed
(unpublished observations during interview with key
expert).
Conclusions
Diabetes represents a public health issue of primary im-
portance for the Italian health system, since it is one of
the major causes of morbidity. The main problem of
diabetes is represented by diabetes-related complica-
tions which reduce life expectancy and cause serious
disabilities such as blindness, amputation, kidney failure
and heart disease. Complications represent a burden
not only from a health perspective, but also from an
economic perspective. Diabetes expenditure represents
currently almost 10% of the total NHS expenditure,
with most of the direct costs being associated with com-
plications, primarily through hospitalization. Diabetes
and related complications affects the health status of
individuals and consequently their working ability and
productive life. Indirect costs should therefore also be
taken into account when assessing the overall economic
burden of diabetes. In Italy, a better assessment of indir-
ect and intangible costs is needed since most of the eco-
nomic studies focus just on direct costs. Although
quality of diabetes care seems to have improved in thelast years, some parameters such as renal function, eyes
examination, and foot monitoring still need to improve.
Moreover, obesity and smoking have increased showing
a difficulty in changing patients’ lifestyles. Overall, Italy
provides a developed system of diabetes care, with
numerous diabetes centres distributed throughout the
country and with treatment free at point of delivery.
The ageing of the Italian population and growing obes-
ity incidence, especially in children, represents the
main threats for the Italian health system. Both ageing
and growing obesity incidence will drive increased
diabetes prevalence in the future, impacting on popula-
tion health status and affecting the NHS economy. It
is essential to focus on prevention, both primary and
secondary, as the main tools to reduce the incidence of
type 2 diabetes-related complications. Preventive inter-
ventions may be more costly in the short term but will
allow future savings. Beside prevention, an improved
diabetes case management will streamline the care
pathways and empower patients, as well as avoid an
unnecessary resource waste. In this regard, the gap
between North and South in the implementation of a
“chronic model of care” should be narrowed with the
South developing a better multidisciplinary and inte-
grated approach to care.
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